Phenylpropylaminopentane is an experimental laboratory compound, reshaped from a Parkinson's drug and explored for learning, drive, and vitality. It has never been given to a person in a published study, so there is no human dose, no half-life, and no safety record. Nearly all favourable work comes from the laboratory that created it, and recent independent testing places it among ordinary stimulants. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated blood pressure | 110–125 / 65–80 mmHg | Earliest sign of sympathetic overstimulation |
| Resting heart rate | 50–65 bpm | Tracks adrenergic load and cardiac strain |
| Corrected QT interval (QTc) | <440 ms (men), <450 ms (women) | Detects the arrhythmia risk that stimulant-class compounds can create |
| Alanine aminotransferase (ALT) | 10–25 U/L (men), 8–20 U/L (women) | Clearance route is unmapped, so liver stress must be watched empirically |
| Serum prolactin | 4–15 ng/mL (men), 4–23 ng/mL (women) | Falls when central dopamine signalling rises, giving an indirect read on the intended mechanism |
| Thyroid-stimulating hormone | 0.5–2.0 mIU/L | Excludes hyperthyroidism, which mimics and compounds stimulant side effects |
| Fasting glucose | 75–90 mg/dL | Catecholamine elevation opposes insulin action and can drift glucose upward |
| Body weight | Change from own baseline | Appetite suppression is the most likely nutritional harm and shows up as weight loss first |
Cadence: Blood pressure and resting heart rate twice daily for the first two weeks, then weekly. Electrocardiogram at four weeks; liver panel and blood count at eight weeks, then every three to six months where exposure continues.